The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer


Cite item

Full Text

Abstract

:Different studies have highlighted the role of Substance P / Neurokinin 1 Receptor (SP/NK-1R) axis in multiple hallmarks of cancer including cell transformation, proliferation, and migration as well as angiogenesis and metastasis of a wide range of solid tumors including colorectal cancer. Until now, the selective high-affinity antagonist of human SP/NK1-R aprepitant (Emend) has been authorized by the Food and Drug Administration as a low dosage medication to manage and treat chemotherapy-induced nausea. However, increasing evidence in recent years support the potential utility of high doses of aprepitant as an antitumor agent and thus, opening the possibility to the pharmacological repositioning of SP/NK1-R antagonists as an adjuvant therapy to conventional cancer treatments. In this review, we summarize current knowledge on the molecular basis of colorectal cancer as well as the pathophysiological importance of SP/NK1-R and the potential utility of SP/NK-1R axis as a therapeutic target in this malignancy.

About the authors

Desirée Martín-García

Surgical Specialties, Biochemistry and Immunology, University of Malaga

Email: info@benthamscience.net

Teresa Téllez

Surgical Specialties, Biochemistry and Immunology, University of Malaga

Email: info@benthamscience.net

Maximino Redondo

Surgical Specialties, Biochemistry and Immunology, University of Malaga

Author for correspondence.
Email: info@benthamscience.net

Marilina García-Aranda

Surgical Specialties, Biochemistry and Immunology,, University of Malaga

Email: info@benthamscience.net

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  2. Siegel, R.L.; Miller, K.D.; Goding Sauer, A.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A. Colorectal cancer statistics, 2020. CA Cancer J. Clin., 2020, 70(3), 145-164. doi: 10.3322/caac.21601 PMID: 32133645
  3. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48. doi: 10.3322/caac.21763 PMID: 36633525
  4. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33. doi: 10.3322/caac.21708 PMID: 35020204
  5. Miller, K.D.; Nogueira, L.; Devasia, T.; Mariotto, A.B.; Yabroff, K.R.; Jemal, A.; Kramer, J.; Siegel, R.L. Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin., 2022, 72(5), 409-436. doi: 10.3322/caac.21731 PMID: 35736631
  6. Oncology, A.S.C. Colorectal Cancer. Statistics, 2022.
  7. Oncology, E.S.f.M. FDA approves first non-invasive dna screening test for colorectal cancer. 2014. Available from: https://www.esmo.org/oncology-news/archive/fda-approves-first-non-invasive-dna-screening-test-for-colorectal-cancer#:~:text=The%20USA%20Food%20and%20Drug,colorectal%20cancer%20or%20its%20precursors.
  8. García-Osogobio, S.M. Early detection of colorectal cancer. Endoscopy, 2013, 25, 88-91.
  9. Diaz Tasende, J.; Marín Gabriel, J. Screening for colorectal cancer by fecal occult blood test. Rev. Esp. Enferm. Dig., 2008, 100, 315-319. PMID: 18752358
  10. Wang, J.; Li, S.; Liu, Y.; Zhang, C.; Li, H.; Lai, B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med., 2020, 9(1), 361-373. doi: 10.1002/cam4.2673 PMID: 31693304
  11. Milette, S.; Sicklick, J.K.; Lowy, A.M.; Brodt, P. Molecular pathways: Targeting the microenvironment of liver metastases. Clin. Cancer Res., 2017, 23(21), 6390-6399. doi: 10.1158/1078-0432.CCR-15-1636 PMID: 28615370
  12. Jin, K.; Gao, W.; Lu, Y.; Lan, H.; Teng, L.; Cao, F. Mechanisms regulating colorectal cancer cell metastasis into liver (Review). Oncol. Lett., 2012, 3(1), 11-15. doi: 10.3892/ol.2011.432 PMID: 22740847
  13. Schirripa, M.; Lenz, H.J. Biomarker in colorectal cancer. Cancer J., 2016, 22(3), 156-164. doi: 10.1097/PPO.0000000000000190 PMID: 27341592
  14. Dekker, E.; Tanis, P.J.; Vleugels, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet, 2019, 394(10207), 1467-1480. doi: 10.1016/S0140-6736(19)32319-0 PMID: 31631858
  15. Testa, U.; Pelosi, E.; Castelli, G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med. Sci. (Basel), 2018, 6(2), 31. doi: 10.3390/medsci6020031 PMID: 29652830
  16. Siegel, R.L.; Fedewa, S.A.; Anderson, W.F.; Miller, K.D.; Ma, J.; Rosenberg, P.S.; Jemal, A. Colorectal cancer incidence patterns in the united states, 1974–2013. J. Natl. Cancer Inst., 2017, 109(8), djw322. doi: 10.1093/jnci/djw322 PMID: 28376186
  17. Whiffin, N.; Hosking, F.J.; Farrington, S.M.; Palles, C.; Dobbins, S.E.; Zgaga, L.; Lloyd, A.; Kinnersley, B.; Gorman, M.; Tenesa, A.; Broderick, P.; Wang, Y.; Barclay, E.; Hayward, C.; Martin, L.; Buchanan, D.D.; Win, A.K.; Hopper, J.; Jenkins, M.; Lindor, N.M.; Newcomb, P.A.; Gallinger, S.; Conti, D.; Schumacher, F.; Casey, G.; Liu, T.; Campbell, H.; Lindblom, A.; Houlston, R.S.; Tomlinson, I.P.; Dunlop, M.G. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. Hum. Mol. Genet., 2014, 23(17), 4729-4737. doi: 10.1093/hmg/ddu177 PMID: 24737748
  18. Hawk, E.T.; Limburg, P.J.; Viner, J.L. Epidemiology and prevention of colorectal cancer. Surg. Clin. North Am., 2002, 82(5), 905-941. doi: 10.1016/S0039-6109(02)00046-4 PMID: 12507200
  19. Fearon, E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol., 2011, 6(1), 479-507. doi: 10.1146/annurev-pathol-011110-130235 PMID: 21090969
  20. Bower, J.J.; Vance, L.D.; Psioda, M.; Smith-Roe, S.L.; Simpson, D.A.; Ibrahim, J.G.; Hoadley, K.A.; Perou, C.M.; Kaufmann, W.K. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. NPJ Breast Cancer, 2017, 3(1), 9. doi: 10.1038/s41523-017-0009-7 PMID: 28649649
  21. Taylor, D.P.; Burt, R.W.; Williams, M.S.; Haug, P.J.; Cannon-Albright, L.A. Population-based family history-specific risks for colorectal cancer: A constellation approach. Gastroenterology, 2010, 138(3), 877-885. doi: 10.1053/j.gastro.2009.11.044 PMID: 19932107
  22. Rustgi, A.K. The genetics of hereditary colon cancer. Genes Dev., 2007, 21(20), 2525-2538. doi: 10.1101/gad.1593107 PMID: 17938238
  23. Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut, 2001, 48(4), 526-535. doi: 10.1136/gut.48.4.526 PMID: 11247898
  24. Gillespie, E.; Leeman, S.E.; Watts, L.A.; Coukos, J.A.; O’Brien, M.J.; Cerda, S.R.; Farraye, F.A.; Stucchi, A.F.; Becker, J.M. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc. Natl. Acad. Sci., 2011, 108(42), 17420-17425. doi: 10.1073/pnas.1114275108 PMID: 21969570
  25. Farraye, F.A.; Odze, R.D.; Eaden, J.; Itzkowitz, S.H.; McCabe, R.P.; Dassopoulos, T.; Lewis, J.D.; Ullman, T.A.; James, T., III; McLeod, R.; Burgart, L.J.; Allen, J.; Brill, J.V. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology, 2010, 138(2), 738-745. doi: 10.1053/j.gastro.2009.12.037 PMID: 20141808
  26. Munkholm, P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2003, 18(Suppl. 2), 1-5. doi: 10.1046/j.1365-2036.18.s2.2.x PMID: 12950413
  27. Kim, E.R.; Chang, D.K. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol., 2014, 20(29), 9872-9881. doi: 10.3748/wjg.v20.i29.9872 PMID: 25110418
  28. Isidro, R.A.; Cruz, M.L.; Isidro, A.A.; Baez, A.; Arroyo, A.; González-Marqués, W.A.; González-Keelan, C.; Torres, E.A.; Appleyard, C.B. Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia. World J. Gastroenterol., 2015, 21(6), 1749-1758. doi: 10.3748/wjg.v21.i6.1749 PMID: 25684939
  29. Nojadeh, J.N.; Behrouz Sharif, S.; Sakhinia, E. Microsatellite instability in colorectal cancer. EXCLI J., 2018, 17, 159-168. doi: 10.17179/excli2017-948 PMID: 29743854
  30. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol., 2006, 7(5), 335-346. doi: 10.1038/nrm1907 PMID: 16612326
  31. Malki, A.; ElRuz, R.A.; Gupta, I.; Allouch, A.; Vranic, S.; Al Moustafa, A.E. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. Int. J. Mol. Sci., 2020, 22(1), 130. doi: 10.3390/ijms22010130 PMID: 33374459
  32. Poynter, J.N.; Siegmund, K.D.; Weisenberger, D.J.; Long, T.I.; Thibodeau, S.N.; Lindor, N.; Young, J.; Jenkins, M.A.; Hopper, J.L.; Baron, J.A.; Buchanan, D.; Casey, G.; Levine, A.J.; Marchand, L.L.; Gallinger, S.; Bapat, B.; Potter, J.D.; Newcomb, P.A.; Haile, R.W.; Laird, P.W. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol. Biomarkers Prev., 2008, 17(11), 3208-3215. doi: 10.1158/1055-9965.EPI-08-0512 PMID: 18990764
  33. Battaglin, F.; Naseem, M.; Lenz, H.J.; Salem, M.E. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin. Adv. Hematol. Oncol., 2018, 16(11), 735-745. PMID: 30543589
  34. Sahin, I.H.; Ciombor, K.K.; Diaz, L.A.; Yu, J.; Kim, R. Immunotherapy for microsatellite stable colorectal cancers: Challenges and novel therapeutic avenues. Am. Soc. Clin. Oncol. Educ. Book, 2022, 42(42), 242-253. doi: 10.1200/EDBK_349811 PMID: 35658496
  35. Poulogiannis, G.; Ichimura, K.; Hamoudi, R.A.; Luo, F.; Leung, S.Y.; Yuen, S.T.; Harrison, D.J.; Wyllie, A.H.; Arends, M.J. Prognostic relevance of DNA copy number changes in colorectal cancer. J. Pathol., 2010, 220(3), 338-347. doi: 10.1002/path.2640 PMID: 19911421
  36. Silva, A.L.; Dawson, S.N.; Arends, M.J.; Guttula, K.; Hall, N.; Cameron, E.A.; Huang, T.H.M.; Brenton, J.D.; Tavaré, S.; Bienz, M.; Ibrahim, A.E.K. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer, 2014, 14(1), 891. doi: 10.1186/1471-2407-14-891 PMID: 25432628
  37. Fodde, R. The APC gene in colorectal cancer. Eur. J. Cancer, 2002, 38(7), 867-871. doi: 10.1016/S0959-8049(02)00040-0 PMID: 11978510
  38. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 1990, 61(5), 759-767. doi: 10.1016/0092-8674(90)90186-I PMID: 2188735
  39. Bienz, M.; Clevers, H. Linking colorectal cancer to Wnt signaling. Cell, 2000, 103(2), 311-320. doi: 10.1016/S0092-8674(00)00122-7 PMID: 11057903
  40. Müller, M.F.; Ibrahim, A.E.K.; Arends, M.J. Molecular pathological classification of colorectal cancer. Virchows Arch., 2016, 469(2), 125-134. doi: 10.1007/s00428-016-1956-3 PMID: 27325016
  41. Liao, W.; Overman, M.J.; Boutin, A.T.; Shang, X.; Zhao, D.; Dey, P.; Li, J.; Wang, G.; Lan, Z.; Li, J.; Tang, M.; Jiang, S.; Ma, X.; Chen, P.; Katkhuda, R.; Korphaisarn, K.; Chakravarti, D.; Chang, A.; Spring, D.J.; Chang, Q.; Zhang, J.; Maru, D.M.; Maeda, D.Y.; Zebala, J.A.; Kopetz, S.; Wang, Y.A.; DePinho, R.A. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell, 2019, 35(4), 559-572.e7. doi: 10.1016/j.ccell.2019.02.008 PMID: 30905761
  42. de Sánchez, M.T.G. Cáncer colorrectal (CCR). Rev. Colomb. Gastroenterol., 2005, 20, 43-53.
  43. Gerstung, M.; Jolly, C.; Leshchiner, I.; Dentro, S.C.; Gonzalez, S.; Rosebrock, D.; Mitchell, T.J.; Rubanova, Y.; Anur, P.; Yu, K.; Tarabichi, M.; Deshwar, A.; Wintersinger, J.; Kleinheinz, K.; Vázquez-García, I.; Haase, K.; Jerman, L.; Sengupta, S.; Macintyre, G.; Malikic, S.; Donmez, N.; Livitz, D.G.; Cmero, M.; Demeulemeester, J.; Schumacher, S.; Fan, Y.; Yao, X.; Lee, J.; Schlesner, M.; Boutros, P.C.; Bowtell, D.D.; Zhu, H.; Getz, G.; Imielinski, M.; Beroukhim, R.; Sahinalp, S.C.; Ji, Y.; Peifer, M.; Markowetz, F.; Mustonen, V.; Yuan, K.; Wang, W.; Morris, Q.D.; Dentro, S.C.; Leshchiner, I.; Gerstung, M.; Jolly, C.; Haase, K.; Tarabichi, M.; Wintersinger, J.; Deshwar, A.G.; Yu, K.; Gonzalez, S.; Rubanova, Y.; Macintyre, G.; Adams, D.J.; Anur, P.; Beroukhim, R.; Boutros, P.C.; Bowtell, D.D.; Campbell, P.J.; Cao, S.; Christie, E.L.; Cmero, M.; Cun, Y.; Dawson, K.J.; Demeulemeester, J.; Donmez, N.; Drews, R.M.; Eils, R.; Fan, Y.; Fittall, M.; Garsed, D.W.; Getz, G.; Ha, G.; Imielinski, M.; Jerman, L.; Ji, Y.; Kleinheinz, K.; Lee, J.; Lee-Six, H.; Livitz, D.G.; Malikic, S.; Markowetz, F.; Martincorena, I.; Mitchell, T.J.; Mustonen, V.; Oesper, L.; Peifer, M.; Peto, M.; Raphael, B.J.; Rosebrock, D.; Sahinalp, S.C.; Salcedo, A.; Schlesner, M.; Schumacher, S.; Sengupta, S.; Shi, R.; Shin, S.J.; Spiro, O.; Stein, L.D.; Vázquez-García, I.; Vembu, S.; Wheeler, D.A.; Yang, T-P.; Yao, X.; Yuan, K.; Zhu, H.; Wang, W.; Morris, Q.D.; Spellman, P.T.; Wedge, D.C.; Van Loo, P.; Spellman, P.T.; Wedge, D.C.; Van Loo, P.; Aaltonen, L.A.; Abascal, F.; Abeshouse, A.; Aburatani, H.; Adams, D.J.; Agrawal, N.; Ahn, K.S.; Ahn, S-M.; Aikata, H.; Akbani, R.; Akdemir, K.C.; Al-Ahmadie, H.; Al-Sedairy, S.T.; Al-Shahrour, F.; Alawi, M.; Albert, M.; Aldape, K.; Alexandrov, L.B.; Ally, A.; Alsop, K.; Alvarez, E.G.; Amary, F.; Amin, S.B.; Aminou, B.; Ammerpohl, O.; Anderson, M.J.; Ang, Y.; Antonello, D.; Anur, P.; Aparicio, S.; Appelbaum, E.L.; Arai, Y.; Aretz, A.; Arihiro, K.; Ariizumi, S.; Armenia, J.; Arnould, L.; Asa, S.; Assenov, Y.; Atwal, G.; Aukema, S.; Auman, J.T.; Aure, M.R.R.; Awadalla, P.; Aymerich, M.; Bader, G.D.; Baez-Ortega, A.; Bailey, M.H.; Bailey, P.J.; Balasundaram, M.; Balu, S.; Bandopadhayay, P.; Banks, R.E.; Barbi, S.; Barbour, A.P.; Barenboim, J.; Barnholtz-Sloan, J.; Barr, H.; Barrera, E.; Bartlett, J.; Bartolome, J.; Bassi, C.; Bathe, O.F.; Baumhoer, D.; Bavi, P.; Baylin, S.B.; Bazant, W.; Beardsmore, D.; Beck, T.A.; Behjati, S.; Behren, A.; Niu, B.; Bell, C.; Beltran, S.; Benz, C.; Berchuck, A.; Bergmann, A.K.; Bergstrom, E.N.; Berman, B.P.; Berney, D.M.; Bernhart, S.H.; Beroukhim, R.; Berrios, M.; Bersani, S.; Bertl, J.; Betancourt, M.; Bhandari, V.; Bhosle, S.G.; Biankin, A.V.; Bieg, M.; Bigner, D.; Binder, H.; Birney, E.; Birrer, M.; Biswas, N.K.; Bjerkehagen, B.; Bodenheimer, T.; Boice, L.; Bonizzato, G.; De Bono, J.S.; Boot, A.; Bootwalla, M.S.; Borg, A.; Borkhardt, A.; Boroevich, K.A.; Borozan, I.; Borst, C.; Bosenberg, M.; Bosio, M.; Boultwood, J.; Bourque, G.; Boutros, P.C.; Bova, G.S.; Bowen, D.T.; Bowlby, R.; Bowtell, D.D.L.; Boyault, S.; Boyce, R.; Boyd, J.; Brazma, A.; Brennan, P.; Brewer, D.S.; Brinkman, A.B.; Bristow, R.G.; Broaddus, R.R.; Brock, J.E.; Brock, M.; Broeks, A.; Brooks, A.N.; Brooks, D.; Brors, B.; Brunak, S.; Bruxner, T.J.C.; Bruzos, A.L.; Buchanan, A.; Buchhalter, I.; Buchholz, C.; Bullman, S.; Burke, H.; Burkhardt, B.; Burns, K.H.; Busanovich, J.; Bustamante, C.D.; Butler, A.P.; Butte, A.J.; Byrne, N.J.; Børresen-Dale, A-L.; Caesar-Johnson, S.J.; Cafferkey, A.; Cahill, D.; Calabrese, C.; Caldas, C.; Calvo, F.; Camacho, N.; Campbell, P.J.; Campo, E.; Cantù, C.; Cao, S.; Carey, T.E.; Carlevaro-Fita, J.; Carlsen, R.; Cataldo, I.; Cazzola, M.; Cebon, J.; Cerfolio, R.; Chadwick, D.E.; Chakravarty, D.; Chalmers, D.; Chan, C.W.Y.; Chan, K.; Chan-Seng-Yue, M.; Chandan, V.S.; Chang, D.K.; Chanock, S.J.; Chantrill, L.A.; Chateigner, A.; Chatterjee, N.; Chayama, K.; Chen, H-W.; Chen, J.; Chen, K.; Chen, Y.; Chen, Z.; Cherniack, A.D.; Chien, J.; Chiew, Y-E.; Chin, S-F.; Cho, J.; Cho, S.; Choi, J.K.; Choi, W.; Chomienne, C.; Chong, Z.; Choo, S.P.; Chou, A.; Christ, A.N.; Christie, E.L.; Chuah, E.; Cibulskis, C.; Cibulskis, K.; Cingarlini, S.; Clapham, P.; Claviez, A.; Cleary, S.; Cloonan, N.; Cmero, M.; Collins, C.C.; Connor, A.A.; Cooke, S.L.; Cooper, C.S.; Cope, L.; Corbo, V.; Cordes, M.G.; Cordner, S.M.; Cortés-Ciriano, I.; Covington, K.; Cowin, P.A.; Craft, B.; Craft, D.; Creighton, C.J.; Cun, Y.; Curley, E.; Cutcutache, I.; Czajka, K.; Czerniak, B.; Dagg, R.A.; Danilova, L.; Davi, M.V.; Davidson, N.R.; Davies, H.; Davis, I.J.; Davis-Dusenbery, B.N.; Dawson, K.J.; De La Vega, F.M.; De Paoli-Iseppi, R.; Defreitas, T.; Tos, A.P.D.; Delaneau, O.; Demchok, J.A.; Demeulemeester, J.; Demidov, G.M.; Demircioğlu, D.; Dennis, N.M.; Denroche, R.E.; Dentro, S.C.; Desai, N.; Deshpande, V.; Deshwar, A.G.; Desmedt, C.; Deu-Pons, J.; Dhalla, N.; Dhani, N.C.; Dhingra, P.; Dhir, R.; DiBiase, A.; Diamanti, K.; Ding, L.; Ding, S.; Dinh, H.Q.; Dirix, L.; Doddapaneni, H.V.; Donmez, N.; Dow, M.T.; Drapkin, R.; Drechsel, O.; Drews, R.M.; Serge, S.; Dudderidge, T.; Dueso-Barroso, A.; Dunford, A.J.; Dunn, M.; Dursi, L.J.; Duthie, F.R.; Dutton-Regester, K.; Eagles, J.; Easton, D.F.; Edmonds, S.; Edwards, P.A.; Edwards, S.E.; Eeles, R.A.; Ehinger, A.; Eils, J.; Eils, R.; El-Naggar, A.; Eldridge, M.; Ellrott, K.; Erkek, S.; Escaramis, G.; Espiritu, S.M.G.; Estivill, X.; Etemadmoghadam, D.; Eyfjord, J.E.; Faltas, B.M.; Fan, D.; Fan, Y.; Faquin, W.C.; Farcas, C.; Fassan, M.; Fatima, A.; Favero, F.; Fayzullaev, N.; Felau, I.; Fereday, S.; Ferguson, M.L.; Ferretti, V.; Feuerbach, L.; Field, M.A.; Fink, J.L.; Finocchiaro, G.; Fisher, C.; Fittall, M.W.; Fitzgerald, A.; Fitzgerald, R.C.; Flanagan, A.M.; Fleshner, N.E.; Flicek, P.; Foekens, J.A.; Fong, K.M.; Fonseca, N.A.; Foster, C.S.; Fox, N.S.; Fraser, M.; Frazer, S.; Frenkel-Morgenstern, M.; Friedman, W.; Frigola, J.; Fronick, C.C.; Fujimoto, A.; Fujita, M.; Fukayama, M.; Fulton, L.A.; Fulton, R.S.; Furuta, M.; Futreal, P.A.; Füllgrabe, A.; Gabriel, S.B.; Gallinger, S.; Gambacorti-Passerini, C.; Gao, J.; Gao, S.; Garraway, L.; Garred, Ø.; Garrison, E.; Garsed, D.W.; Gehlenborg, N.; Gelpi, J.L.L.; George, J.; Gerhard, D.S.; Gerhauser, C.; Gershenwald, J.E.; Gerstein, M.; Gerstung, M.; Getz, G.; Ghori, M.; Ghossein, R.; Giama, N.H.; Gibbs, R.A.; Gibson, B.; Gill, A.J.; Gill, P.; Giri, D.D.; Glodzik, D.; Gnanapragasam, V.J.; Goebler, M.E.; Goldman, M.J.; Gomez, C.; Gonzalez, S.; Gonzalez-Perez, A.; Gordenin, D.A.; Gossage, J.; Gotoh, K.; Govindan, R.; Grabau, D.; Graham, J.S.; Grant, R.C.; Green, A.R.; Green, E.; Greger, L.; Grehan, N.; Grimaldi, S.; Grimmond, S.M.; Grossman, R.L.; Grundhoff, A.; Gundem, G.; Guo, Q.; Gupta, M.; Gupta, S.; Gut, I.G.; Gut, M.; Göke, J.; Ha, G.; Haake, A.; Haan, D.; Haas, S.; Haase, K.; Haber, J.E.; Habermann, N.; Hach, F.; Haider, S.; Hama, N.; Hamdy, F.C.; Hamilton, A.; Hamilton, M.P.; Han, L.; Hanna, G.B.; Hansmann, M.; Haradhvala, N.J.; Harismendy, O.; Harliwong, I.; Harmanci, A.O.; Harrington, E.; Hasegawa, T.; Haussler, D.; Hawkins, S.; Hayami, S.; Hayashi, S.; Hayes, D.N.; Hayes, S.J.; Hayward, N.K.; Hazell, S.; He, Y.; Heath, A.P.; Heath, S.C.; Hedley, D.; Hegde, A.M.; Heiman, D.I.; Heinold, M.C.; Heins, Z.; Heisler, L.E.; Hellstrom-Lindberg, E.; Helmy, M.; Heo, S.G.; Hepperla, A.J.; Heredia-Genestar, J.M.; Herrmann, C.; Hersey, P.; Hess, J.M.; Hilmarsdottir, H.; Hinton, J.; Hirano, S.; Hiraoka, N.; Hoadley, K.A.; Hobolth, A.; Hodzic, E.; Hoell, J.I.; Hoffmann, S.; Hofmann, O.; Holbrook, A.; Holik, A.Z.; Hollingsworth, M.A.; Holmes, O.; Holt, R.A.; Hong, C.; Hong, E.P.; Hong, J.H.; Hooijer, G.K.; Hornshøj, H.; Hosoda, F.; Hou, Y.; Hovestadt, V.; Howat, W.; Hoyle, A.P.; Hruban, R.H.; Hu, J.; Hu, T.; Hua, X.; Huang, K.; Huang, M.; Huang, M.N.; Huang, V.; Huang, Y.; Huber, W.; Hudson, T.J.; Hummel, M.; Hung, J.A.; Huntsman, D.; Hupp, T.R.; Huse, J.; Huska, M.R.; Hutter, B.; Hutter, C.M.; Hübschmann, D.; Iacobuzio-Donahue, C.A.; Imbusch, C.D.; Imielinski, M.; Imoto, S.; Isaacs, W.B.; Isaev, K.; Ishikawa, S.; Iskar, M.; Islam, S.M.A.; Ittmann, M.; Ivkovic, S.; Izarzugaza, J.M.G.; Jacquemier, J.; Jakrot, V.; Jamieson, N.B.; Jang, G.H.; Jang, S.J.; Jayaseelan, J.C.; Jayasinghe, R.; Jefferys, S.R.; Jegalian, K.; Jennings, J.L.; Jeon, S-H.; Jerman, L.; Ji, Y.; Jiao, W.; Johansson, P.A.; Johns, A.L.; Johns, J.; Johnson, R.; Johnson, T.A.; Jolly, C.; Joly, Y.; Jonasson, J.G.; Jones, C.D.; Jones, D.R.; Jones, D.T.W.; Jones, N.; Jones, S.J.M.; Jonkers, J.; Ju, Y.S.; Juhl, H.; Jung, J.; Juul, M.; Juul, R.I.; Juul, S.; Jäger, N.; Kabbe, R.; Kahles, A.; Kahraman, A.; Kaiser, V.B.; Kakavand, H.; Kalimuthu, S.; von Kalle, C.; Kang, K.J.; Karaszi, K.; Karlan, B.; Karlić, R.; Karsch, D.; Kasaian, K.; Kassahn, K.S.; Katai, H.; Kato, M.; Katoh, H.; Kawakami, Y.; Kay, J.D.; Kazakoff, S.H.; Kazanov, M.D.; Keays, M.; Kebebew, E.; Kefford, R.F.; Kellis, M.; Kench, J.G.; Kennedy, C.J.; Kerssemakers, J.N.A.; Khoo, D.; Khoo, V.; Khuntikeo, N.; Khurana, E.; Kilpinen, H.; Kim, H.K.; Kim, H-L.; Kim, H-Y.; Kim, H.; Kim, J.; Kim, J.; Kim, J.K.; Kim, Y.; King, T.A.; Klapper, W.; Kleinheinz, K.; Klimczak, L.J.; Knappskog, S.; Kneba, M.; Knoppers, B.M.; Koh, Y.; Komorowski, J.; Komura, D.; Komura, M.; Kong, G.; Kool, M.; Korbel, J.O.; Korchina, V.; Korshunov, A.; Koscher, M.; Koster, R.; Kote-Jarai, Z.; Koures, A.; Kovacevic, M.; Kremeyer, B.; Kretzmer, H.; Kreuz, M.; Krishnamurthy, S.; Kube, D.; Kumar, K.; Kumar, P.; Kumar, S.; Kumar, Y.; Kundra, R.; Kübler, K.; Küppers, R.; Lagergren, J.; Lai, P.H.; Laird, P.W.; Lakhani, S.R.; Lalansingh, C.M.; Lalonde, E.; Lamaze, F.C.; Lambert, A.; Lander, E.; Landgraf, P.; Landoni, L.; Langerød, A.; Lanzós, A.; Larsimont, D.; Larsson, E.; Lathrop, M.; Lau, L.M.S.; Lawerenz, C.; Lawlor, R.T.; Lawrence, M.S.; Lazar, A.J.; Lazic, A.M.; Le, X.; Lee, D.; Lee, D.; Lee, E.A.; Lee, H.J.; Lee, J.J-K.; Lee, J-Y.; Lee, J.; Lee, M.T.M.; Lee-Six, H.; Lehmann, K-V.; Lehrach, H.; Lenze, D.; Leonard, C.R.; Leongamornlert, D.A.; Leshchiner, I.; Letourneau, L.; Letunic, I.; Levine, D.A.; Lewis, L.; Ley, T.; Li, C.; Li, C.H.; Li, H.I.; Li, J.; Li, L.; Li, S.; Li, S.; Li, X.; Li, X.; Li, X.; Li, Y.; Liang, H.; Liang, S-B.; Lichter, P.; Lin, P.; Lin, Z.; Linehan, W.M.; Lingjærde, O.C.; Liu, D.; Liu, E.M.; Liu, F-F.F.; Liu, F.; Liu, J.; Liu, X.; Livingstone, J.; Livitz, D.; Livni, N.; Lochovsky, L.; Loeffler, M.; Long, G.V.; Lopez-Guillermo, A.; Lou, S.; Louis, D.N.; Lovat, L.B.; Lu, Y.; Lu, Y-J.; Lu, Y.; Luchini, C.; Lungu, I.; Luo, X.; Luxton, H.J.; Lynch, A.G.; Lype, L.; López, C.; López-Otín, C.; Ma, E.Z.; Ma, Y.; MacGrogan, G.; MacRae, S.; Macintyre, G.; Madsen, T.; Maejima, K.; Mafficini, A.; Maglinte, D.T.; Maitra, A.; Majumder, P.P.; Malcovati, L.; Malikic, S.; Malleo, G.; Mann, G.J.; Mantovani-Löffler, L.; Marchal, K.; Marchegiani, G.; Mardis, E.R.; Margolin, A.A.; Marin, M.G.; Markowetz, F.; Markowski, J.; Marks, J.; Marques-Bonet, T.; Marra, M.A.; Marsden, L.; Martens, J.W.M.; Martin, S.; Martin-Subero, J.I.; Martincorena, I.; Martinez- Fundichely, A.; Maruvka, Y.E.; Mashl, R.J.; Massie, C.E.; Matthew, T.J.; Matthews, L.; Mayer, E.; Mayes, S.; Mayo, M.; Mbabaali, F.; McCune, K.; McDermott, U.; McGillivray, P.D.; McLellan, M.D.; McPherson, J.D.; McPherson, J.R.; McPherson, T.A.; Meier, S.R.; Meng, A.; Meng, S.; Menzies, A.; Merrett, N.D.; Merson, S.; Meyerson, M.; Meyerson, W.; Mieczkowski, P.A.; Mihaiescu, G.L.; Mijalkovic, S.; Mikkelsen, T.; Milella, M.; Mileshkin, L.; Miller, C.A.; Miller, D.K.; Miller, J.K.; Mills, G.B.; Milovanovic, A.; Minner, S.; Miotto, M.; Arnau, G.M.; Mirabello, L.; Mitchell, C.; Mitchell, T.J.; Miyano, S.; Miyoshi, N.; Mizuno, S.; Molnár-Gábor, F.; Moore, M.J.; Moore, R.A.; Morganella, S.; Morris, Q.D.; Morrison, C.; Mose, L.E.; Moser, C.D.; Muiños, F.; Mularoni, L.; Mungall, A.J.; Mungall, K.; Musgrove, E.A.; Mustonen, V.; Mutch, D.; Muyas, F.; Muzny, D.M.; Muñoz, A.; Myers, J.; Myklebost, O.; Möller, P.; Nagae, G.; Nagrial, A.M.; Nahal- Bose, H.K.; Nakagama, H.; Nakagawa, H.; Nakamura, H.; Nakamura, T.; Nakano, K.; Nandi, T.; Nangalia, J.; Nastic, M.; Navarro, A.; Navarro, F.C.P.; Neal, D.E.; Nettekoven, G.; Newell, F.; Newhouse, S.J.; Newton, Y.; Ng, A.W.T.; Ng, A.; Nicholson, J.; Nicol, D.; Nie, Y.; Nielsen, G.P.; Nielsen, M.M.; Nik-Zainal, S.; Noble, M.S.; Nones, K.; Northcott, P.A.; Notta, F.; O’Connor, B.D.; O’Donnell, P.; O’Donovan, M.; O’Meara, S.; O’Neill, B.P.; O’Neill, J.R.; Ocana, D.; Ochoa, A.; Oesper, L.; Ogden, C.; Ohdan, H.; Ohi, K.; Ohno-Machado, L.; Oien, K.A.; Ojesina, A.I.; Ojima, H.; Okusaka, T.; Omberg, L.; Ong, C.K.; Ossowski, S.; Ott, G.; Ouellette, B.F.F.; P’ng, C.; Paczkowska, M.; Paiella, S.; Pairojkul, C.; Pajic, M.; Pan-Hammarström, Q.; Papaemmanuil, E.; Papatheodorou, I.; Paramasivam, N.; Park, J.W.; Park, J-W.; Park, K.; Park, K.; Park, P.J.; Parker, J.S.; Parsons, S.L.; Pass, H.; Pasternack, D.; Pastore, A.; Patch, A-M.; Pauporté, I.; Pea, A.; Pearson, J.V.; Pedamallu, C.S.; Pedersen, J.S.; Pederzoli, P.; Peifer, M.; Pennell, N.A.; Perou, C.M.; Perry, M.D.; Petersen, G.M.; Peto, M.; Petrelli, N.; Petryszak, R.; Pfister, S.M.; Phillips, M.; Pich, O.; Pickett, H.A.; Pihl, T.D.; Pillay, N.; Pinder, S.; Pinese, M.; Pinho, A.V.; Pitkänen, E.; Pivot, X.; Piñeiro-Yáñez, E.; Planko, L.; Plass, C.; Polak, P.; Pons, T.; Popescu, I.; Potapova, O.; Prasad, A.; Preston, S.R.; Prinz, M.; Pritchard, A.L.; Prokopec, S.D.; Provenzano, E.; Puente, X.S.; Puig, S.; Puiggròs, M.; Pulido-Tamayo, S.; Pupo, G.M.; Purdie, C.A.; Quinn, M.C.; Rabionet, R.; Rader, J.S.; Radlwimmer, B.; Radovic, P.; Raeder, B.; Raine, K.M.; Ramakrishna, M.; Ramakrishnan, K.; Ramalingam, S.; Raphael, B.J.; Rathmell, W.K.; Rausch, T.; Reifenberger, G.; Reimand, J.; Reis-Filho, J.; Reuter, V.; Reyes-Salazar, I.; Reyna, M.A.; Reynolds, S.M.; Rheinbay, E.; Riazalhosseini, Y.; Richardson, A.L.; Richter, J.; Ringel, M.; Ringnér, M.; Rino, Y.; Rippe, K.; Roach, J.; Roberts, L.R.; Roberts, N.D.; Roberts, S.A.; Robertson, A.G.; Robertson, A.J.; Rodriguez, J.B.; Rodriguez-Martin, B.; Rodríguez-González, F.G.; Roehrl, M.H.A.; Rohde, M.; Rokutan, H.; Romieu, G.; Rooman, I.; Roques, T.; Rosebrock, D.; Rosenberg, M.; Rosenstiel, P.C.; Rosenwald, A.; Rowe, E.W.; Royo, R.; Rozen, S.G.; Rubanova, Y.; Rubin, M.A.; Rubio-Perez, C.; Rudneva, V.A.; Rusev, B.C.; Ruzzenente, A.; Rätsch, G.; Sabarinathan, R.; Sabelnykova, V.Y.; Sadeghi, S.; Sahinalp, S.C.; Saini, N.; Saito-Adachi, M.; Saksena, G.; Salcedo, A.; Salgado, R.; Salichos, L.; Sallari, R.; Saller, C.; Salvia, R.; Sam, M.; Samra, J.S.; Sanchez-Vega, F.; Sander, C.; Sanders, G.; Sarin, R.; Sarrafi, I.; Sasaki-Oku, A.; Sauer, T.; Sauter, G.; Saw, R.P.M.; Scardoni, M.; Scarlett, C.J.; Scarpa, A.; Scelo, G.; Schadendorf, D.; Schein, J.E.; Schilhabel, M.B.; Schlesner, M.; Schlomm, T.; Schmidt, H.K.; Schramm, S-J.; Schreiber, S.; Schultz, N.; Schumacher, S.E.; Schwarz, R.F.; Scolyer, R.A.; Scott, D.; Scully, R.; Seethala, R.; Segre, A.V.; Selander, I.; Semple, C.A.; Senbabaoglu, Y.; Sengupta, S.; Sereni, E.; Serra, S.; Sgroi, D.C.; Shackleton, M.; Shah, N.C.; Shahabi, S.; Shang, C.A.; Shang, P.; Shapira, O.; Shelton, T.; Shen, C.; Shen, H.; Shepherd, R.; Shi, R.; Shi, Y.; Shiah, Y-J.; Shibata, T.; Shih, J.; Shimizu, E.; Shimizu, K.; Shin, S.J.; Shiraishi, Y.; Shmaya, T.; Shmulevich, I.; Shorser, S.I.; Short, C.; Shrestha, R.; Shringarpure, S.S.; Shriver, C.; Shuai, S.; Sidiropoulos, N.; Siebert, R.; Sieuwerts, A.M.; Sieverling, L.; Signoretti, S.; Sikora, K.O.; Simbolo, M.; Simon, R.; Simons, J.V.; Simpson, J.T.; Simpson, P.T.; Singer, S.; Sinnott-Armstrong, N.; Sipahimalani, P.; Skelly, T.J.; Smid, M.; Smith, J.; Smith-McCune, K.; Socci, N.D.; Sofia, H.J.; Soloway, M.G.; Song, L.; Sood, A.K.; Sothi, S.; Sotiriou, C.; Soulette, C.M.; Span, P.N.; Spellman, P.T.; Sperandio, N.; Spillane, A.J.; Spiro, O.; Spring, J.; Staaf, J.; Stadler, P.F.; Staib, P.; Stark, S.G.; Stebbings, L.; Stefánsson, Ó.A.; Stegle, O.; Stein, L.D.; Stenhouse, A.; Stewart, C.; Stilgenbauer, S.; Stobbe, M.D.; Stratton, M.R.; Stretch, J.R.; Struck, A.J.; Stuart, J.M.; Stunnenberg, H.G.; Su, H.; Su, X.; Sun, R.X.; Sungalee, S.; Susak, H.; Suzuki, A.; Sweep, F.; Szczepanowski, M.; Sültmann, H.; Yugawa, T.; Tam, A.; Tamborero, D.; Tan, B.K.T.; Tan, D.; Tan, P.; Tanaka, H.; Taniguchi, H.; Tanskanen, T.J.; Tarabichi, M.; Tarnuzzer, R.; Tarpey, P.; Taschuk, M.L.; Tatsuno, K.; Tavaré, S.; Taylor, D.F.; Taylor-Weiner, A.; Teague, J.W.; Teh, B.T.; Tembe, V.; Temes, J.; Thai, K.; Thayer, S.P.; Thiessen, N.; Thomas, G.; Thomas, S.; Thompson, A.; Thompson, A.M.; Thompson, J.F.F.; Thompson, R.H.; Thorne, H.; Thorne, L.B.; Thorogood, A.; Tiao, G.; Tijanic, N.; Timms, L.E.; Tirabosco, R.; Tojo, M.; Tommasi, S.; Toon, C.W.; Toprak, U.H.; Torrents, D.; Tortora, G.; Tost, J.; Totoki, Y.; Townend, D.; Traficante, N.; Treilleux, I.; Trotta, J-R.; Trümper, L.H.P.; Tsao, M.; Tsunoda, T.; Tubio, J.M.C.; Tucker, O.; Turkington, R.; Turner, D.J.; Tutt, A.; Ueno, M.; Ueno, N.T.; Umbricht, C.; Umer, H.M.; Underwood, T.J.; Urban, L.; Urushidate, T.; Ushiku, T.; Uusküla-Reimand, L.; Valencia, A.; Van Den Berg, D.J.; Van Laere, S.; Van Loo, P.; Van Meir, E.G.; Van den Eynden, G.G.; Van der Kwast, T.; Vasudev, N.; Vazquez, M.; Vedururu, R.; Veluvolu, U.; Vembu, S.; Verbeke, L.P.C.; Vermeulen, P.; Verrill, C.; Viari, A.; Vicente, D.; Vicentini, C.; VijayRaghavan, K.; Viksna, J.; Vilain, R.E.; Villasante, I.; Vincent-Salomon, A.; Visakorpi, T.; Voet, D.; Vyas, P.; Vázquez-García, I.; Waddell, N.M.; Waddell, N.; Wadelius, C.; Wadi, L.; Wagener, R.; Wala, J.A.; Wang, J.; Wang, J.; Wang, L.; Wang, Q.; Wang, W.; Wang, Y.; Wang, Z.; Waring, P.M.; Warnatz, H-J.; Warrell, J.; Warren, A.Y.; Waszak, S.M.; Wedge, D.C.; Weichenhan, D.; Weinberger, P.; Weinstein, J.N.; Weischenfeldt, J.; Weisenberger, D.J.; Welch, I.; Wendl, M.C.; Werner, J.; Whalley, J.P.; Wheeler, D.A.; Whitaker, H.C.; Wigle, D.; Wilkerson, M.D.; Williams, A.; Wilmott, J.S.; Wilson, G.W.; Wilson, J.M.; Wilson, R.K.; Winterhoff, B.; Wintersinger, J.A.; Wiznerowicz, M.; Wolf, S.; Wong, B.H.; Wong, T.; Wong, W.; Woo, Y.; Wood, S.; Wouters, B.G.; Wright, A.J.; Wright, D.W.; Wright, M.H.; Wu, C-L.; Wu, D-Y.; Wu, G.; Wu, J.; Wu, K.; Wu, Y.; Wu, Z.; Xi, L.; Xia, T.; Xiang, Q.; Xiao, X.; Xing, R.; Xiong, H.; Xu, Q.; Xu, Y.; Xue, H.; Yachida, S.; Yakneen, S.; Yamaguchi, R.; Yamaguchi, T.N.; Yamamoto, M.; Yamamoto, S.; Yamaue, H.; Yang, F.; Yang, H.; Yang, J.Y.; Yang, L.; Yang, L.; Yang, S.; Yang, T-P.; Yang, Y.; Yao, X.; Yaspo, M-L.; Yates, L.; Yau, C.; Ye, C.; Ye, K.; Yellapantula, V.D.; Yoon, C.J.; Yoon, S-S.; Yousif, F.; Yu, J.; Yu, K.; Yu, W.; Yu, Y.; Yuan, K.; Yuan, Y.; Yuen, D.; Yung, C.K.; Zaikova, O.; Zamora, J.; Zapatka, M.; Zenklusen, J.C.; Zenz, T.; Zeps, N.; Zhang, C-Z.; Zhang, F.; Zhang, H.; Zhang, H.; Zhang, H.; Zhang, J.; Zhang, J.; Zhang, J.; Zhang, X.; Zhang, X.; Zhang, Y.; Zhang, Z.; Zhao, Z.; Zheng, L.; Zheng, X.; Zhou, W.; Zhou, Y.; Zhu, B.; Zhu, H.; Zhu, J.; Zhu, S.; Zou, L.; Zou, X.; deFazio, A.; van As, N.; van Deurzen, C.H.M.; van de Vijver, M.J.; van’t Veer, L.; von Mering, C. The evolutionary history of 2,658 cancers. Nature, 2020, 578(7793), 122-128. doi: 10.1038/s41586-019-1907-7 PMID: 32025013
  44. Boutin, A.T.; Liao, W.T.; Wang, M.; Hwang, S.S.; Karpinets, T.V.; Cheung, H.; Chu, G.C.; Jiang, S.; Hu, J.; Chang, K.; Vilar, E.; Song, X.; Zhang, J.; Kopetz, S.; Futreal, A.; Wang, Y.A.; Kwong, L.N.; DePinho, R.A. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev., 2017, 31(4), 370-382. doi: 10.1101/gad.293449.116 PMID: 28289141
  45. Quirke, P.; Risio, M.; Lambert, R.; von Karsa, L.; Vieth, M. Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations. Virchows Arch., 2011, 458(1), 1-19. doi: 10.1007/s00428-010-0977-6 PMID: 21061133
  46. Snover, D.C. Update on the serrated pathway to colorectal carcinoma. Hum. Pathol., 2011, 42(1), 1-10. doi: 10.1016/j.humpath.2010.06.002 PMID: 20869746
  47. Takai, D.; Jones, P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci., 2002, 99(6), 3740-3745. doi: 10.1073/pnas.052410099 PMID: 11891299
  48. Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.P.J. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci., 1999, 96(15), 8681-8686. doi: 10.1073/pnas.96.15.8681 PMID: 10411935
  49. Noffsinger, A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu. Rev. Pathol., 2009, 4(1), 343-364. doi: 10.1146/annurev.pathol.4.110807.092317 PMID: 19400693
  50. East, J.E.; Saunders, B.P.; Jass, J.R. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am., 2008, 37(1), 25-46, v. doi: 10.1016/j.gtc.2007.12.014 PMID: 18313538
  51. Snover, D.C. Serrated polyps of the large intestine. Semin. Diagn. Pathol., 2005, 22(4), 301-308. doi: 10.1053/j.semdp.2006.04.003 PMID: 16939058
  52. Snover, D.C.; Jass, J.R.; Fenoglio-Preiser, C.; Batts, K.P. Serrated polyps of the large intestine: A morphologic and molecular review of an evolving concept. Am. J. Clin. Pathol., 2005, 124(3), 380-391. doi: 10.1309/V2EPTPLJRB3FGHJL PMID: 16191506
  53. Jeong, M.; Goodell, M.A. New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells. Exp. Hematol., 2014, 42(8), 609-617. doi: 10.1016/j.exphem.2014.04.008 PMID: 24993071
  54. Kaur, H.; Bhalla, S.; Raghava, G.P.S. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. PLoS One, 2019, 14(9), e0221476. doi: 10.1371/journal.pone.0221476 PMID: 31490960
  55. Hu, J.; Zhao, F.; Huang, B.; Ran, J.; Chen, M.; Liu, H.; Deng, Y.; Zhao, X.; Han, X. An eight-CpG-based methylation classifier for preoperative discriminating early and advanced-late stage of colorectal cancer. Front. Genet., 2021, 11, 614160. doi: 10.3389/fgene.2020.614160 PMID: 33519917
  56. Nazemalhosseini Mojarad, E.; Kuppen, P.J.; Aghdaei, H.A.; Zali, M.R. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol. Hepatol. Bed Bench, 2013, 6(3), 120-128. PMID: 24834258
  57. Jass, J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology, 2007, 50(1), 113-130. doi: 10.1111/j.1365-2559.2006.02549.x PMID: 17204026
  58. De Rosa, M.; Rega, D.; Costabile, V.; Duraturo, F.; Niglio, A.; Izzo, P.; Pace, U.; Delrio, P. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap. Adv. Gastroenterol., 2016, 9(6), 861-886. doi: 10.1177/1756283X16659790 PMID: 27803741
  59. Barault, L.; Charon-Barra, C.; Jooste, V.; de la Vega, M.F.; Martin, L.; Roignot, P.; Rat, P.; Bouvier, A.M.; Laurent-Puig, P.; Faivre, J.; Chapusot, C.; Piard, F. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res., 2008, 68(20), 8541-8546. doi: 10.1158/0008-5472.CAN-08-1171 PMID: 18922929
  60. Yagi, K.; Akagi, K.; Hayashi, H.; Nagae, G.; Tsuji, S.; Isagawa, T. Three epigenotypes of DNA methylation in human colorectal cancer. Clin. Cancer Res., 2010, 16, 21-33. doi: 10.1158/1078-0432.CCR-09-2006 PMID: 20028768
  61. Shen, L.; Catalano, P.J.; Benson, A.B., III; O’Dwyer, P.; Hamilton, S.R.; Issa, J.P.J. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res., 2007, 13(20), 6093-6098. doi: 10.1158/1078-0432.CCR-07-1011 PMID: 17947473
  62. Guinney, J.; Dienstmann, R.; Wang, X.; de Reyniès, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; Bot, B.M.; Morris, J.S.; Simon, I.M.; Gerster, S.; Fessler, E.; De Sousa E Melo, F.; Missiaglia, E.; Ramay, H.; Barras, D.; Homicsko, K.; Maru, D.; Manyam, G.C.; Broom, B.; Boige, V.; Perez-Villamil, B.; Laderas, T.; Salazar, R.; Gray, J.W.; Hanahan, D.; Tabernero, J.; Bernards, R.; Friend, S.H.; Laurent-Puig, P.; Medema, J.P.; Sadanandam, A.; Wessels, L.; Delorenzi, M.; Kopetz, S.; Vermeulen, L.; Tejpar, S. The consensus molecular subtypes of colorectal cancer. Nat. Med., 2015, 21(11), 1350-1356. doi: 10.1038/nm.3967 PMID: 26457759
  63. Rebersek, M. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision. Radiol. Oncol., 2020, 54(3), 272-277. doi: 10.2478/raon-2020-0031 PMID: 32463385
  64. Park, S.C.; Sohn, D.K.; Kim, M.J.; Chang, H.J.; Han, K.S.; Hyun, J.H.; Joo, J.; Oh, J.H. Phase II clinical trial to evaluate the efficacy of transanal endoscopic total mesorectal excision for rectal cancer. Dis. Colon Rectum, 2018, 61(5), 554-560. doi: 10.1097/DCR.0000000000001058 PMID: 29624549
  65. Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019, 69(5), 363-385. doi: 10.3322/caac.21565 PMID: 31184787
  66. Ogura, A.; Konishi, T.; Cunningham, C.; Garcia-Aguilar, J.; Iversen, H.; Toda, S.; Lee, I.K.; Lee, H.X.; Uehara, K.; Lee, P.; Putter, H.; van de Velde, C.J.H.; Beets, G.L.; Rutten, H.J.T.; Kusters, M. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J. Clin. Oncol., 2019, 37(1), 33-43. doi: 10.1200/JCO.18.00032 PMID: 30403572
  67. Johdi, N.A.; Sukor, N.F. Colorectal cancer immunotherapy: Options and strategies. Front. Immunol., 2020, 11, 1624. doi: 10.3389/fimmu.2020.01624 PMID: 33042104
  68. Pardini, B.; Kumar, R.; Naccarati, A.; Novotny, J.; Prasad, R.B.; Forsti, A.; Hemminki, K.; Vodicka, P.; Lorenzo Bermejo, J. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br. J. Clin. Pharmacol., 2011, 72(1), 162-163. doi: 10.1111/j.1365-2125.2010.03892.x PMID: 21204909
  69. Calvo, E.; Cortés, J.; Rodríguez, J.; Fernández-Hidalgo, Ó.; Rebollo, J.; Martín-Algarra, S.; García-Foncillas, J.; Martínez-Monge, R.; de Irala, J.; Brugarolas, A. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: A phase II study. Clin. Colorectal Cancer, 2002, 2(2), 104-110. doi: 10.3816/CCC.2002.n.016 PMID: 12453325
  70. Yuan, Y.; Xiao, W.W.; Xie, W.H.; Cai, P.Q.; Wang, Q.X.; Chang, H.; Chen, B.Q.; Zhou, W.H.; Zeng, Z.F.; Wu, X.J.; Liu, Q.; Li, L.R.; Zhang, R.; Gao, Y.H. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: A potential improvement to overall survival and decrease to multivisceral resection. BMC Cancer, 2021, 21(1), 179. doi: 10.1186/s12885-021-07894-6 PMID: 33607964
  71. Zheng, S.; Tao, W. Identification of novel transcriptome signature as a potential prognostic biomarker for anti-angiogenic therapy in glioblastoma multiforme. Cancers, 2020, 12 doi: 10.3390/cancers12092368 PMID: 33804433
  72. Hao, Z.; Parasramka, S.; Chen, Q.; Jacob, A.; Huang, B.; Mullett, T.; Benson, A.B. Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs. Oncologist, 2022, 28(1), 48-58. doi: 10.1093/oncolo/oyac209 PMID: 36200844
  73. Normanno, N.; Tejpar, S.; Morgillo, F.; De Luca, A.; Van Cutsem, E.; Ciardiello, F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol., 2009, 6(9), 519-527. doi: 10.1038/nrclinonc.2009.111 PMID: 19636327
  74. Shen, W.D.; Chen, H.L.; Liu, P.F. EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: A meta-analysis. Chin. J. Cancer Res., 2014, 26(1), 59-71. doi: 10.3978/j.issn.1000-9604.2014.01.10 PMID: 24653627
  75. Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist, 2007, 12(3), 356-361. doi: 10.1634/theoncologist.12-3-356 PMID: 17405901
  76. Tang, P.A.; Cohen, S.J.; Kollmannsberger, C.; Bjarnason, G.; Virik, K.; MacKenzie, M.J.; Lourenco, L.; Wang, L.; Chen, A.; Moore, M.J. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin. Cancer Res., 2012, 18(21), 6023-6031. doi: 10.1158/1078-0432.CCR-11-3252 PMID: 22977191
  77. Piawah, S.; Venook, A.P. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer, 2019, 125(23), 4139-4147. doi: 10.1002/cncr.32163 PMID: 31433498
  78. Wojtukiewicz, M.Z.; Rek, M.M.; Karpowicz, K.; Górska, M.; Polityńska, B.; Wojtukiewicz, A.M.; Moniuszko, M.; Radziwon, P.; Tucker, S.C.; Honn, K.V. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev., 2021, 40(3), 949-982. doi: 10.1007/s10555-021-09976-0 PMID: 34236546
  79. Patsoukis, N.; Brown, J.; Petkova, V.; Liu, F.; Li, L.; Boussiotis, V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal., 2012, 5(230), ra46. doi: 10.1126/scisignal.2002796 PMID: 22740686
  80. García-Aranda, M.; Redondo, M. Immunotherapy: A challenge of breast cancer treatment. Cancers, 2019, 11(12), 1822. doi: 10.3390/cancers11121822 PMID: 31756919
  81. FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer. 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer#:~:text=On%20July%2031%2C%202017%2C%20the,colorectal%20cancer%20that%20has%20progressed
  82. Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res., 2019, 25(13), 3753-3758. doi: 10.1158/1078-0432.CCR-18-4070 PMID: 30787022
  83. Administration, F.a.D.. FDA approves first-line immunotherapy for patients with MSI-H/dMMR metastatic. 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer#:~:text=On%20June%2029%2C%202020%2C%20the,deficient%20(dMMR)%20colorectal%20cancer.
  84. André, T.; Shiu, K.K.; Kim, T.W.; Jensen, B.V.; Jensen, L.H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; de la Fouchardiere, C.; Rivera, F.; Elez, E.; Bendell, J.; Le, D.T.; Yoshino, T.; Van Cutsem, E.; Yang, P.; Farooqui, M.Z.H.; Marinello, P.; Diaz, L.A., Jr Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med., 2020, 383(23), 2207-2218. doi: 10.1056/NEJMoa2017699 PMID: 33264544
  85. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication
  86. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer. 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer
  87. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; Biedrzycki, B.; Donehower, R.C.; Zaheer, A.; Fisher, G.A.; Crocenzi, T.S.; Lee, J.J.; Duffy, S.M.; Goldberg, R.M.; de la Chapelle, A.; Koshiji, M.; Bhaijee, F.; Huebner, T.; Hruban, R.H.; Wood, L.D.; Cuka, N.; Pardoll, D.M.; Papadopoulos, N.; Kinzler, K.W.; Zhou, S.; Cornish, T.C.; Taube, J.M.; Anders, R.A.; Eshleman, J.R.; Vogelstein, B.; Diaz, L.A., Jr PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med., 2015, 372(26), 2509-2520. doi: 10.1056/NEJMoa1500596 PMID: 26028255
  88. de Wied, D. Peptide hormones and neuropeptides: birds of a feather. Trends Neurosci., 2000, 23(3), 113. doi: 10.1016/S0166-2236(99)01511-8 PMID: 10675911
  89. Burbach, J.P. Neuropeptides from concept to online database. J. Pharmacol, 2010, 626, 27-48.
  90. Hökfelt, T.; Bartfai, T.; Bloom, F. Neuropeptides: opportunities for drug discovery. Lancet Neurol., 2003, 2(8), 463-472. doi: 10.1016/S1474-4422(03)00482-4 PMID: 12878434
  91. Romanova, E.V.; Sweedler, J.V. Peptidomics for the discovery and characterization of neuropeptides and hormones. Trends Pharmacol. Sci., 2015, 36(9), 579-586. doi: 10.1016/j.tips.2015.05.009 PMID: 26143240
  92. Steinhoff, M.S.; von Mentzer, B.; Geppetti, P.; Pothoulakis, C.; Bunnett, N.W. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev., 2014, 94(1), 265-301. doi: 10.1152/physrev.00031.2013 PMID: 24382888
  93. Martínez, A.N.; Philipp, M.T. Substance P and neuoquinin-1 receptor antagonists in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J. Neurol. Neuromedicine, 2016, 1, 29-36. doi: 10.29245/2572.942X/2016/2.1020 PMID: 27430034
  94. Werge, T. The tachykinin tale: Molecular recognition in a historical perspective. J. Mol. Recognit., 2007, 20(3), 145-153. doi: 10.1002/jmr.822 PMID: 17444559
  95. Bremer, A.A.; Leeman, S.E.; Boyd, N.D. The common C-terminal sequences of substance P and neurokinin A contact the same region of the NK-1 receptor. FEBS Lett., 2000, 486(1), 43-48. doi: 10.1016/S0014-5793(00)02228-6 PMID: 11108840
  96. Goldsmith, L.E.; Kwatra, M.M. Tachykinin/substance P/neurokinin-1 receptors.Encyclopedia of Biological Chemistry; Academic Press: Waltham, MA, 2013, pp. 360-365.
  97. Lorestani, S.; Ghahremanloo, A.; Jangjoo, A.; Abedi, M.; Hashemy, S.I. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol. Biol. Rep., 2020, 47(5), 3469-3474. doi: 10.1007/s11033-020-05432-4 PMID: 32277443
  98. García-Aranda, M.; Téllez, T.; McKenna, L.; Redondo, M. Neurokinin-1 receptor-1 (NK-1R) antagonists as a new strategy to overcome cancer resistance. Cancers, 2022, 14(9), 2255. doi: 10.3390/cancers14092255 PMID: 35565383
  99. Patacchini, R.; Maggi, C.A. Peripheral tachykinin receptors as targets for new drugs. Eur. J. Pharmacol., 2001, 429(1-3), 13-21. doi: 10.1016/S0014-2999(01)01301-2 PMID: 11698023
  100. NCBI TAC1 Precursor de taquiquinina 1 Homo Sapiens (humano). Available from: https://www.ncbi.nlm.nih.gov/gene/6863 (Accessed August 16, 2022).
  101. Page, N.M. New challenges in the study of the mammalian tachykinins. Peptides, 2005, 26(8), 1356-1368. doi: 10.1016/j.peptides.2005.03.030 PMID: 16042976
  102. El gen TAC3 de la base de datos de genes humanos. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TAC3 (Accessed August 16, 2022).
  103. NCBI TAC3 Precursor de taquiquinina 3 Homo Sapiens (humano). Available from: https://www.ncbi.nlm.nih.gov/gene/6866 (Accessed August 16, 2022).
  104. UNIProt UniProtKB–Q86UU9 (TKN4_HUMAN). Available from: https://www.uniprot.org/uniprot/Q86UU9 (Accessed August 16, 2022).
  105. NCBI TAC4 Precursor de taquiquinina 4 Homo Sapiens (humano). Available from: https://www.ncbi.nlm.nih.gov/gene/255061 (Accessed August 16, 2022).
  106. Ho, W.Z.; Lai, J.P.; Zhu, X.H.; Uvaydova, M.; Douglas, S.D. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J. Immunol., 1997, 159(11), 5654-5660. doi: 10.4049/jimmunol.159.11.5654 PMID: 9548509
  107. McGillis, J.P.; Mitsuhashi, M.; Payan, D.G. Immunological properties of substance P. In: Psychoneuroimmunology; Ader, R., Ed.; Academic Press, 1991; pp. 209-223. doi: 10.1016/B978-0-12-043780-1.50011-7
  108. Moore, T.C.; Lami, J.L.; Spruck, C.H. Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep. Immunology, 1989, 67(1), 109-114. PMID: 2472354
  109. Stanisz, A.M.; Befus, D.; Bienenstock, J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer’s patches, mesenteric lymph nodes, and spleen. J. Immunol., 1986, 136(1), 152-156. doi: 10.4049/jimmunol.136.1.152 PMID: 2415614
  110. Lotz, M.; Vaughan, J.H.; Carson, D.A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science, 1988, 241(4870), 1218-1221. doi: 10.1126/science.2457950 PMID: 2457950
  111. Hartung, H.P.; Toyka, K.V. Activation of macrophages by substance P: Induction of oxidative burst and thromboxane release. Eur. J. Pharmacol., 1983, 89(3-4), 301-305. doi: 10.1016/0014-2999(83)90511-3 PMID: 6191998
  112. Muñoz, M.; Coveñas, R. Neurokinin receptor antagonism: A patent review (2014-present). Expert Opin. Ther. Pat., 2020, 30(7), 527-539. doi: 10.1080/13543776.2020.1769599 PMID: 32401556
  113. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454(7203), 436-444. doi: 10.1038/nature07205 PMID: 18650914
  114. Rosso, M.; Muñoz, M.; Berger, M. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal, 2012, 2012, 1-21. doi: 10.1100/2012/381434 PMID: 22545017
  115. Feng, F.; Yang, J.; Tong, L.; Yuan, S.; Tian, Y.; Hong, L.; Wang, W.; Zhang, H. Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol. Int., 2011, 35(6), 623-629. doi: 10.1042/CBI20100229 PMID: 21091434
  116. Bar-Shavit, Z.; Goldman, R.; Stabinsky, Y.; Gottlieb, P.; Fridkin, M.; Teichberg, V.I.; Blumberg, S. Enhancement of phagocytosis - A newly found activity of Substance P residing in its N-terminal tetrapeptide sequence. Biochem. Biophys. Res. Commun., 1980, 94(4), 1445-1451. doi: 10.1016/0006-291X(80)90581-1 PMID: 6156684
  117. Kage, R.; Leeman, S.E.; Boyd, N.D. Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland. J. Neurochem., 1993, 60(1), 347-351. doi: 10.1111/j.1471-4159.1993.tb05857.x PMID: 8380195
  118. UniProt UniProtKB-P25103. Available from: https://www.uniprot.org/uniprot/P25103 (Accessed Jul 5, 2023)
  119. Gerard, N.P.; Garraway, L.A.; Eddy, R.L. Human substance P receptor (NK-1): Gene organization, chromosomal localization, and functional expression of cDNA clones. Biochemistry, 1991, 30, 10640-10646. doi: 10.1021/bi00108a006 PMID: 1657150
  120. O’Connor, T.M.; O’Connell, J.; O’Brien, D.I.; Goode, T.; Bredin, C.P.; Shanahan, F. The role of substance P in inflammatory disease. J. Cell. Physiol., 2004, 201(2), 167-180. doi: 10.1002/jcp.20061 PMID: 15334652
  121. Lai, J.P.; Lai, S.; Tuluc, F.; Tansky, M.F.; Kilpatrick, L.E.; Leeman, S.E.; Douglas, S.D. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc. Natl. Acad. Sci., 2008, 105(34), 12605-12610. doi: 10.1073/pnas.0806632105 PMID: 18713853
  122. Ghahremanloo, A.; Javid, H.; Afshari, A.R.; Hashemy, S.I. Investigation of the role of neurokinin-1 receptor inhibition with aprepitant in apoptotic cell death via PI3K/Akt/NF- κ B signal transduction pathways in colon cancer cells. BioMed Res. Int., 2021, 2021, 1-10. doi: 10.1155/2021/1383878 PMID: 34395609
  123. Spitsin, S.; Pappa, V.; Douglas, S.D. Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling. J. Leukoc. Biol., 2018, 103(6), 1043-1051. doi: 10.1002/JLB.3MIR0817-348R PMID: 29345372
  124. Ramkissoon, S.H.; Patel, P.S.; Taborga, M.; Rameshwar, P. Nuclear factor kappaB is critical for truncated neurokinin-1 receptor expression in breast cancer: Implication for quiescence of breast cancer cells within the bone marrow stroma. Cancer Res., 2007, 67, 1653-1659. doi: 10.1158/0008-5472.CAN-06-3813 PMID: 17308106
  125. Patel, H.J.; Ramkissoon, S.H.; Patel, P.S.; Rameshwar, P. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc. Natl. Acad. Sci., 2005, 102(48), 17436-17441. doi: 10.1073/pnas.0506351102 PMID: 16291810
  126. Bigioni, M.; Benzo, A.; Irrissuto, C.; Maggi, C.A.; Goso, C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs, 2005, 16(10), 1083-1089. doi: 10.1097/00001813-200511000-00007 PMID: 16222150
  127. Gao, X.; Wang, Z. Difference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma. Oncol. Lett., 2017, 14(3), 3729-3733. doi: 10.3892/ol.2017.6588 PMID: 28927139
  128. Isorna, I.; Esteban, F.; Solanellas, J.; Coveñas, R.; Muñoz, M. The substance P and neurokinin-1 receptor system in human thyroid cancer: An immunohistochemical study. Eur. J. Histochem., 2020, 64(2), 3117. doi: 10.4081/ejh.2020.3117 PMID: 32363847
  129. Hennig, I.M.; Laissue, J.A.; Horisberger, U.; Reubi, J.C. Substance-P receptors in human primary neoplasms: Tumoral and vascular localization. Int. J. Cancer, 1995, 61(6), 786-792. doi: 10.1002/ijc.2910610608 PMID: 7790112
  130. Muñoz, M.; Coveñas, R. Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J. Gastroenterol., 2014, 20(9), 2321-2334. doi: 10.3748/wjg.v20.i9.2321 PMID: 24605029
  131. Javid, H.; Asadi, J.; Zahedi Avval, F.; Afshari, A.R.; Hashemy, S.I. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways. Mol. Biol. Rep., 2020, 47(3), 2253-2263. doi: 10.1007/s11033-020-05330-9 PMID: 32072401
  132. Douglas, S.D.; Leeman, S.E. Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation. Ann. N. Y. Acad. Sci., 2011, 1217(1), 83-95. doi: 10.1111/j.1749-6632.2010.05826.x PMID: 21091716
  133. Liu, R.; Chen, Y.; Liu, G.; Li, C.; Song, Y.; Cao, Z.; Li, W.; Hu, J.; Lu, C.; Liu, Y. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis., 2020, 11(9), 797. doi: 10.1038/s41419-020-02998-6 PMID: 32973135
  134. Salaroglio, I.C.; Mungo, E.; Gazzano, E.; Kopecka, J.; Riganti, C. ERK is a pivotal player of chemo-immune-resistance in cancer. Int. J. Mol. Sci., 2019, 20(10), 2505. doi: 10.3390/ijms20102505 PMID: 31117237
  135. DeFea, K.A.; Vaughn, Z.D.; O’Bryan, E.M.; Nishijima, D.; Déry, O.; Bunnett, N.W. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc. Natl. Acad. Sci., 2000, 97(20), 11086-11091. doi: 10.1073/pnas.190276697 PMID: 10995467
  136. Deng, X.T.; Tang, S.M.; Wu, P.Y.; Li, Q.P.; Ge, X.X.; Xu, B.M.; Wang, H.S.; Miao, L. SP/NK-1R promotes gallbladder cancer cell proliferation and migration. J. Cell. Mol. Med., 2019, 23(12), 7961-7973. doi: 10.1111/jcmm.14230 PMID: 30903649
  137. Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M.P.; Bours, V. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22(1), 90-97. doi: 10.1038/sj.onc.1206056 PMID: 12527911
  138. Di Maio, M.; Bria, E.; Banna, G.L.; Puglisi, F.; Garassino, M.C.; Lorusso, D.; Perrone, F. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors. Anticancer Drugs, 2013, 24(2), 99-111. doi: 10.1097/CAD.0b013e328359d7ba PMID: 23165435
  139. Cassidy, J.; Clarke, S.; Díaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.S.; Rivera, F.; Couture, F.; Sirzén, F.; Saltz, L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(12), 2006-2012. doi: 10.1200/JCO.2007.14.9898 PMID: 18421053
  140. Shimokawa, M.; Hayashi, T.; Nishimura, J.; Satoh, T.; Fukunaga, M.; Matsui, R.; Tsuji, Y.; Mizuki, F.; Kogawa, T. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. BMC Cancer, 2021, 21(1), 1111. doi: 10.1186/s12885-021-08860-y PMID: 34656107
  141. Vidall, C.; Fernández-Ortega, P.; Cortinovis, D.; Jahn, P.; Amlani, B.; Scotté, F. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: A cross-sectional multinational survey. Support. Care Cancer, 2015, 23(11), 3297-3305. doi: 10.1007/s00520-015-2750-5 PMID: 25953380
  142. Hesketh, P.J. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 2008, 358(23), 2482-2494. doi: 10.1056/NEJMra0706547 PMID: 18525044
  143. Navari, R.M. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin. Drug Saf., 2016, 15(3), 343-356. doi: 10.1517/14740338.2016.1135899 PMID: 26699406
  144. Hesketh, P.J.; Kris, M.G.; Basch, E.; Bohlke, K.; Barbour, S.Y.; Clark-Snow, R.A.; Danso, M.A.; Dennis, K.; Dupuis, L.L.; Dusetzina, S.B.; Eng, C.; Feyer, P.C.; Jordan, K.; Noonan, K.; Sparacio, D.; Somerfield, M.R.; Lyman, G.H. Antiemetics: Update to the american society of clinical oncology clinical practice guideline. J. Clin. Oncol., 2017, 35(28), 3240-3261. doi: 10.1200/JCO.2017.74.4789 PMID: 28759346
  145. Navari, R.M.; Aapro, M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 2016, 374(14), 1356-1367. doi: 10.1056/NEJMra1515442 PMID: 27050207
  146. Schwartzberg, L.S.; Modiano, M.R.; Rapoport, B.L.; Chasen, M.R.; Gridelli, C.; Urban, L.; Poma, A.; Arora, S.; Navari, R.M.; Schnadig, I.D. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol., 2015, 16(9), 1071-1078. doi: 10.1016/S1470-2045(15)00034-0 PMID: 26272768
  147. Aapro, M. CINV: Patients still worrying after all these years. Cancer Support Care, 2018, 26, 5-9. doi: 10.1007/s00520-018-4131-3 PMID: 29556808
  148. European Medicines Agency EMEND. INN-Aprepitant: Scientific Discussion. 2004. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/emend-epar-scientific-discussion_en.pdf (Accessed August 17, 2022)
  149. Muñoz, M.; Coveñas, R. The neurokinin-1 receptor antagonist aprepitant: A smart bullet against cancer? Cancers, 2020, 12(9), 2682. doi: 10.3390/cancers12092682 PMID: 32962202
  150. Robinson, P.; Kasembeli, M.; Bharadwaj, U.; Engineer, N.; Eckols, K.T.; Tweardy, D.J.; Substance, P. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. BioMed Res. Int., 2016, 2016, 1-9. doi: 10.1155/2016/1959270 PMID: 26981525
  151. Muñoz, M.; González-Ortega, A.; Salinas-Martín, M.V.; Carranza, A.; Garcia-Recio, S.; Almendro, V.; Coveñas, R. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. Int. J. Oncol., 2014, 45(4), 1658-1672. doi: 10.3892/ijo.2014.2565 PMID: 25175857
  152. Nizam, E.; Erin, N. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Biomed. Pharmacother., 2018, 108, 263-270. doi: 10.1016/j.biopha.2018.09.013 PMID: 30223097
  153. Zhang, X.W.; Li, L.; Hu, W.Q.; Hu, M.N.; Tao, Y.; Hu, H.; Miao, X.K.; Yang, W.L.; Zhu, Q.; Mou, L.Y. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR. Cell Death Dis., 2022, 13(1), 41. doi: 10.1038/s41419-021-04485-y PMID: 35013118
  154. Matalińska, J.; Świć, A.; Lipiński, P.; Misicka, A. Antiproliferative effects of D-Pro2, D-Trp7,9-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells. Folia Neuropathol., 2020, 58(3), 237-244. doi: 10.5114/fn.2020.100066 PMID: 33099293
  155. Muñoz, M.; Coveñas, R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides, 2013, 48, 1-9. doi: 10.1016/j.peptides.2013.07.024 PMID: 23933301
  156. Beirith, I.; Renz, B.W.; Mudusetti, S.; Ring, N.S.; Kolorz, J.; Koch, D.; Bazhin, A.V.; Berger, M.; Wang, J.; Angele, M.K.; D’Haese, J.G.; Guba, M.O.; Niess, H.; Andrassy, J.; Werner, J.; Ilmer, M. Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer. Cancers, 2021, 13(11), 2703. doi: 10.3390/cancers13112703 PMID: 34070805
  157. Ebrahimi, S.; Mirzavi, F.; Aghaee-Bakhtiari, S.H.; Hashemy, S.I. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant. Biochim. Biophys. Acta Mol. Cell Res., 2022, 1869(5), 119221. doi: 10.1016/j.bbamcr.2022.119221 PMID: 35134443
  158. Takei, S.; Ishibe, A.; Watanabe, J.; Watanabe, K.; Suwa, Y.; Suzuki, S.; Nakagawa, K.; Suwa, H.; Ota, M.; Ichikawa, Y.; Kunisaki, C.; Yamanaka, T.; Endo, I. Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: A prospective cohort study (YCOG1301). Int. J. Colorectal Dis., 2020, 35(12), 2323-2329. doi: 10.1007/s00384-020-03731-7 PMID: 32860080
  159. Garnier, A.; Vykoukal, J.; Hubertus, J.; Alt, E.; Von Schweinitz, D.; Kappler, R.; Berger, M.; Ilmer, M. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int. J. Oncol., 2015, 47(1), 151-160. doi: 10.3892/ijo.2015.3016 PMID: 25998227
  160. Ghahremanloo, A.; Javid, H.; Afshari, A.R.; Hashemy, S.I. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells. BioMed Res. Int., 2021, 2021, 1-10. doi: 10.1155/2021/1383878 PMID: 34395609
  161. Koon, H.W.; Zhao, D.; Na, X.; Moyer, M.P.; Pothoulakis, C. Metalloproteinases and transforming growth factor-α mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J. Biol. Chem., 2004, 279(44), 45519-45527. doi: 10.1074/jbc.M408523200 PMID: 15319441
  162. Stucchi, A.F.; Shofer, S.; Leeman, S.; Materne, O.; Beer, E.; McClung, J.; Shebani, K.; Moore, F.; O’Brien, M.; Becker, J.M. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279(6), G1298-G1306. doi: 10.1152/ajpgi.2000.279.6.G1298 PMID: 11093954
  163. Castagliuolo, I.; Morteau, O.; Keates, A.C.; Valenick, L.; Wang, C.C.; Zacks, J.; Lu, B.; Gerard, N.P.; Pothoulakis, C. Protective effects of neurokinin-1 receptor during colitis in mice: Role of the epidermal growth factor receptor. Br. J. Pharmacol., 2002, 136(2), 271-279. doi: 10.1038/sj.bjp.0704697 PMID: 12010776
  164. Rosso, M.; Robles-Frías, M.J.; Coveñas, R.; Salinas-Martín, M.V.; Muñoz, M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol., 2008, 29(4), 245-254. doi: 10.1159/000152942 PMID: 18781096
  165. Pagán, B.; Isidro, A.A.; Coppola, D.; Chen, Z.; Ren, Y.; Wu, J.; Appleyard, C.B. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res., 2010, 30(9), 3345-3353. PMID: 20944107
  166. Legi, A.; Rodriguez, E.; Eckols, T.K.; Mistry, C.; Robinson, P.; Substance, P. Substance P antagonism prevents chemotherapy-induced cardiotoxicity. Cancers, 2021, 13(7), 1732. doi: 10.3390/cancers13071732 PMID: 33917491
  167. Rapoport, B.; Aapro, M.; Chasen, M.; Jordan, K.; Navari, R.; Schnadig, I.; Schwartzberg, L. Recent developments in the clinical pharmacology of rolapitant: Subanalyses in specific populations. Drug Des. Devel. Ther., 2017, 11, 2621-2629. doi: 10.2147/DDDT.S133943 PMID: 28919712
  168. Lee, M.; McCloskey, M.; Staples, S. Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels. Int. J. Cancer Clin. Res., 2016, 3, 071. doi: 10.23937/2378-3419/3/6/1071
  169. Muñoz, M.; Crespo, J.C.; Crespo, J.P.; Coveñas, R. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. Mol. Clin. Oncol., 2019, 11(1), 50-54. doi: 10.3892/mco.2019.1857 PMID: 31289677
  170. FDA. Approves first cancer treatment for any solid tumor with a specific genetic feature. 2017. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature (Accessed on: February 5, 2023)
  171. Zhao, L.; Lee, V.H.F.; Ng, M.K.; Yan, H.; Bijlsma, M.F. Molecular subtyping of cancer: Current status and moving toward clinical applications. Brief. Bioinform., 2019, 20(2), 572-584. doi: 10.1093/bib/bby026 PMID: 29659698

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers